Brief: Brii Biosciences Adds US$100 Million To Advance Its Late-Stage Monoclonal Antibody Combination Therapy, Brii-196/Brii-198, For Non-Hospitalized Covid-19 Patients
07/09/2021 12:10
Sept 7 (Reuters) - Brii Biosciences Ltd 2137.HK :
* BRII BIOSCIENCES ADDS US$100 MILLION TO ADVANCE ITS
LATE-STAGE
MONOCLONAL ANTIBODY COMBINATION THERAPY, BRII-196/BRII-198, FOR
NON-HOSPITALIZED COVID-19 PATIENTS
Source text for Eikon: ID:nPn4bTv0Ha
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR